Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes
11 Sep 2023
Drug Approval
Preview
Source: PMLiVE
Eli Lilly’s Mounjaro (tirzepatide) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for poorly controlled type 2 diabetes in adults, alongside diet and exercise.
According to NICE’s draft guidance, around 180,000 people living with difficult-to-manage type 2 diabetes could benefit from the new treatment option.
The recommendation follows additional analyses and modelling on clinical and cost-effectiveness provided by Lilly, following a request by NICE.
Evidence from clinical trials showed that Mounjaro resulted in significant reductions in blood sugar levels and body weight in comparison to Novo Nordisk’s semaglutide injection, insulin therapy or a placebo.
The new treatment option resulted in 81% to 97% of people reaching better glucose control, and 54% to 88% reaching a 5% or greater reduction in body weight, which was significantly more than the comparators.
Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonistglucagon-like peptide-1 (GLP-1) receptor agonist for adults with type 2 diabetes when metformin, the main first-line medicine for type 2 diabetes, cannot be tolerated.
Over five million people in the UK live with diabetes, 90% of whom are estimated to have type 2, according to Diabetes UKDiabetes UK.
Helen Knight, director of medicines evaluation at NICE, said: "Our committee recognised the potential [Mounjaro] has to provide an effective and good value treatment option for all those living with poorly controlled type 2 diabetes.
"This recommendation will offer fresh hope for many and provide value for money for the taxpayer."
Douglas Twenefour, head of care at Diabetes UKDiabetes UK, said: "We welcome NICE’s decision to approve Mounjaro to be prescribed on the NHS as this will provide another effective treatment option for managing type 2 diabetes."
In May 2022, Mounjaro received approval from the US Food and Drug Administration for the treatment of adults with type 2 diabetes, alongside diet and exercise, making it the first and only US-approved GIP and GLP-1 receptor agonist.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.